Subscribe
Menu
Login
Search
Login
Subscribe
News & Opinion
Publications
AN INTERACTIVE EXPERIENCE
Current Issue
June 2022, Issue 2
Preview This Issue
Archives
Features
Quarterly Magazine
Current Issue
Summer 2022
Preview This Issue
Archives
Features
Categories
Biochemistry
Cancer
Cell Biology
Community
Drug Development
Environment
Evolution
Genetics
Immunology
Microbiology
Neuroscience
Physiology
Public Health
Zoology
Multimedia
Crossword Puzzles
Infographics
Science Snapshot
Words for Nerds
Videos
Webinars
Research Resources
Podcasts
Events
Infographics
eBooks
Videos
The Scientist University
Research Products Blog
Articles
Home
Subjects
BioTime
BioTime
Geron hESC Trial to Resume?
Jef Akst | May 27, 2014
Nearly three years after Geron shuttered its stem cell program, BioTime receives funding to relaunch a Phase 1 trial for spinal cord injury.
Geron Sells Stem Cell Assets
Beth Marie Mole | Jan 8, 2013
BioTime finalizes a deal to buy Geron’s defunct human embryonic stem cell assets.